| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $199,403 | 1 | 7 |
Sells | $19,502,554 | 14 | 93 |
| Fox Jonathan C | director | 1 | $199,403 | 0 | $0 | $199,403 |
| MOORE JOHN R | General Counsel | 0 | $0 | 1 | $219,823 | $-219,823 |
| Derakhshan Behrad | Chief Business Officer | 0 | $0 | 1 | $223,424 | $-223,424 |
| KOCH KEVIN | President and CEO | 0 | $0 | 1 | $785,042 | $-785,042 |
| Edris Badreddin | director | 0 | $0 | 1 | $3.4M | $-3.4M |
| Donovan Joanne M. | CMO | 0 | $0 | 7 | $4.62M | $-4.62M |
| Russell Alan J | Chief Scientific Officer | 0 | $0 | 3 | $10.25M | $-10.25M |
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle …
Over the last 12 months, insiders at Edgewise Therapeutics, Inc. have bought $199,403 and sold $19.5M worth of Edgewise Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Edgewise Therapeutics, Inc. have bought $12.32M and sold $9M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Fox Jonathan C (director) — $199,403.
The last purchase of 10,700 shares for transaction amount of $199,403 was made by Fox Jonathan C (director) on 2025‑11‑11.
| 2026-08-13 | Sale | Donovan Joanne M. | CMO | 2,919 0.0027% | $43.41 | $126,704 | -4.68% | |
| 2026-08-12 | Sale | KOCH KEVIN | President and CEO | 17,971 0.0168% | $43.68 | $785,042 | -5.23% | |
| 2026-08-12 | Sale | Derakhshan Behrad | Chief Business Officer | 5,100 0.0048% | $43.81 | $223,424 | -5.23% | |
| 2026-08-12 | Sale | Russell Alan J | Chief Scientific Officer | 5,901 0.0055% | $43.73 | $258,042 | -5.23% | |
| 2026-08-12 | Sale | MOORE JOHN R | General Counsel | 5,016 0.0047% | $43.82 | $219,823 | -5.23% | |
| 2026-08-12 | Sale | Donovan Joanne M. | CMO | 6,522 0.0061% | $43.85 | $286,000 | -5.23% | |
| 2026-07-01 | Sale | Russell Alan J | Chief Scientific Officer | 200,000 0.1871% | $39.41 | $7.88M | +5.03% | |
| 2026-05-05 | Sale | Donovan Joanne M. | CMO | 50,000 0.0572% | $38.57 | $1.93M | +4.59% | |
| 2026-05-04 | Sale | Donovan Joanne M. | CMO | 5,230 0.0049% | $31.29 | $163,663 | +26.39% | |
| 2026-04-01 | Sale | Donovan Joanne M. | CMO | 28,662 0.0261% | $32.31 | $926,095 | +18.38% | |
| 2026-03-31 | Sale | Donovan Joanne M. | CMO | 21,338 0.0203% | $32.12 | $685,308 | +24.48% | |
| 2026-03-27 | Sale | Donovan Joanne M. | CMO | 16,358 0.0153% | $30.98 | $506,735 | +27.04% | |
| 2026-01-21 | Sale | Edris Badreddin | director | 115,471 0.1098% | $29.44 | $3.4M | +25.36% | |
| 2025-11-12 | Sale | Russell Alan J | Chief Scientific Officer | 100,000 0.1163% | $21.12 | $2.11M | +58.48% | |
| 2025-11-11 | Fox Jonathan C | director | 10,700 0.011% | $18.64 | $199,403 | +56.15% | ||
| 2025-08-26 | Sale | Russell Alan J | Chief Scientific Officer | 100,000 0.0933% | $14.60 | $1.46M | +103.97% | |
| 2025-08-12 | Sale | Carruthers R Michael | Chief Financial Officer | 1,428 0.0014% | $13.39 | $19,124 | +118.37% | |
| 2025-08-12 | Sale | KOCH KEVIN | President and CEO | 7,972 0.0078% | $13.39 | $106,764 | +118.37% | |
| 2025-08-12 | Sale | Donovan Joanne M. | CMO | 2,862 0.0028% | $13.39 | $38,329 | +118.37% | |
| 2025-08-12 | Sale | Derakhshan Behrad | Chief Business Officer | 2,491 0.0024% | $13.39 | $33,360 | +118.37% |
| Fox Jonathan C | director | 23702 0.022% | $893,091.36 | 2 | 0 | +90.07% |
| ORBIMED ADVISORS LLC | 14809075 13.764% | $558.01M | 5 | 0 | +3.23% | |
| Thompson Peter A. | 14809075 13.764% | $558.01M | 5 | 0 | +3.23% | |
| OrbiMed Genesis GP LLC | 13497456 12.5449% | $508.58M | 1 | 0 | +30.03% | |
| Novo Holdings A/S | 10 percent owner | 6071703 5.6432% | $228.78M | 2 | 0 | <0.0001% |
| Flynn James E | 10 percent owner | 3933137 3.6556% | $148.2M | 1 | 0 | <0.0001% |
| ROOT JONATHAN D | director | 15625 0.0145% | $588,750.00 | 1 | 0 | <0.0001% |
$224,662,742 | 52 | 32.03% | $5.65B | |
$11,583,737 | 45 | 49.75% | $4.66B | |
$104,428,685 | 44 | 22.55% | $3.78B | |
$151,136,640 | 31 | -1.41% | $3.95B | |
$5,066,938 | 27 | 26.38% | $3.7B |
| Increased Positions | 117 | +64.29% | 18M | +15.81% |
| Decreased Positions | 76 | -41.76% | 7M | -6.12% |
| New Positions | 45 | New | 4M | New |
| Sold Out Positions | 21 | Sold Out | 1M | Sold Out |
| Total Postitions | 223 | +22.53% | 123M | +9.68% |
| Orbimed Advisors Llc | $368,564.00 | 14.64% | 15.52M | 0 | 0% | 2025-09-30 |
| Ra Capital Management, L.P. | $247,675.00 | 9.84% | 10.43M | +525,804 | +5.31% | 2025-09-30 |
| Baker Bros. Advisors Lp | $173,516.00 | 6.89% | 7.31M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $150,848.00 | 5.99% | 6.35M | -429,559 | -6.33% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $146,541.00 | 5.82% | 6.17M | +27,787 | +0.45% | 2025-09-30 |
| Novo Holdings A/S | $127,063.00 | 5.05% | 5.35M | 0 | 0% | 2025-09-30 |
| Braidwell Lp | $123,757.00 | 4.92% | 5.21M | 0 | 0% | 2025-09-30 |
| Janus Henderson Group Plc | $118,259.00 | 4.7% | 4.98M | -524,018 | -9.52% | 2025-09-30 |
| Vanguard Group Inc | $114,094.00 | 4.53% | 4.8M | -37,559 | -0.78% | 2025-09-30 |
| Cormorant Asset Management, Lp | $95,238.00 | 3.78% | 4.01M | -241,992 | -5.69% | 2025-09-30 |